Spots Global Cancer Trial Database for furmonertinib

Every month we try and update this database with for furmonertinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC	NCT05987826	Non-Small Cell ...	Furmonertinib	18 Years - 75 Years	Shanghai Zhongshan Hospital
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases	NCT05379803	Non-Small Cell ...	Furmonertinib	18 Years -	Hunan Province Tumor Hospital
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC	NCT04895930	Non-Small-Cell ...	Furmonertinib Anlotinib	18 Years - 75 Years	Shanghai Chest Hospital
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases	NCT06319950	Lung Cancer, No...	Furmonertinib Osimertinib	18 Years - 80 Years	Taizhou Hospital
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）	NCT05465343	Furmonertinib EGFR-mutation NSCLC Brain Metastase...	Furmonertinib	18 Years -	Peking Union Medical College
Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)	NCT04965831	Lung Adenocarci...	Furmonertinib	18 Years - 75 Years	Tianjin Medical University Cancer Institute and Hospital
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas	NCT05079022	Adenocarcinoma ...	Furmonertinib	18 Years -	Peking University People's Hospital
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion	NCT05466149	NSCLC	Furmonertinib	18 Years -	Allist Pharmaceuticals, Inc.
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis	NCT06352502	EGF-R Positive ... CNS Metastases	Furmonertinib	18 Years -	Tang-Du Hospital
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas	NCT05079022	Adenocarcinoma ...	Furmonertinib	18 Years -	Peking University People's Hospital
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis	NCT06339242	NSCLC	Furmonertinib	18 Years - 75 Years	Jiangsu Province Nanjing Brain Hospital
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC	NCT04895930	Non-Small-Cell ...	Furmonertinib Anlotinib	18 Years - 75 Years	Shanghai Chest Hospital
Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（iFORCE）	NCT05465343	Furmonertinib EGFR-mutation NSCLC Brain Metastase...	Furmonertinib	18 Years -	Peking Union Medical College
ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas	NCT05079022	Adenocarcinoma ...	Furmonertinib	18 Years -	Peking University People's Hospital
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases	NCT05379803	Non-Small Cell ...	Furmonertinib	18 Years -	Hunan Province Tumor Hospital
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression	NCT04970693	Non-small Cell ... Oligoprogressiv...	Furmonertinib	18 Years - 80 Years	Sun Yat-sen University
Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC	NCT05813522	Non Small Cell ...	Furmonertinib M...	18 Years -	First Affiliated Hospital of Zhejiang University
Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities	NCT04982900	Multiple Primar...	furmonertinib Placebo	18 Years - 80 Years	Ruijin Hospital
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy	NCT06192849	Non Small Cell ... EGFR Exon 20 In...	Furmonertinib	18 Years -	Sichuan Cancer Hospital and Research Institute
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion	NCT05466149	NSCLC	Furmonertinib	18 Years -	Allist Pharmaceuticals, Inc.
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC	NCT05987826	Non-Small Cell ...	Furmonertinib	18 Years - 75 Years	Shanghai Zhongshan Hospital
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC	NCT05994131	NSCLC	IN10018 Furmonertinib	18 Years -	InxMed (Shanghai) Co., Ltd.
The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC	NCT06117644	Non Small Cell ... EGFR Gene Mutat... Non Small Cell ... Non-small Cell ...	Furmonertinib	18 Years -	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression	NCT04970693	Non-small Cell ... Oligoprogressiv...	Furmonertinib	18 Years - 80 Years	Sun Yat-sen University
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma	NCT05503667	Lung Adenocarci... Lung Adenocarci... EGFR Gene Mutat...	Furmonertinib Bevacizumab	18 Years -	Shanghai Pulmonary Hospital, Shanghai, China
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases	NCT06319950	Lung Cancer, No...	Furmonertinib Osimertinib	18 Years - 80 Years	Taizhou Hospital
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy	NCT06192849	Non Small Cell ... EGFR Exon 20 In...	Furmonertinib	18 Years -	Sichuan Cancer Hospital and Research Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: